Aclaris Therapeutics, Inc.
ACRS
$3.59
$0.298.79%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -64.92M | -141.68M | -134.65M | -130.21M | -132.07M |
| Total Depreciation and Amortization | 454.00K | 495.00K | 564.00K | 692.00K | 807.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 14.68M | 99.82M | 100.67M | 99.21M | 100.26M |
| Change in Net Operating Assets | 2.67M | -1.56M | 23.43M | 17.99M | 10.92M |
| Cash from Operations | -47.11M | -42.92M | -9.99M | -12.32M | -20.08M |
| Capital Expenditure | -111.00K | -87.00K | -64.00K | -29.00K | -121.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 48.48M | -50.64M | -61.70M | -67.45M | -69.65M |
| Cash from Investing | 48.37M | -50.73M | -61.76M | -67.48M | -69.77M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 80.00M | 80.03M | 80.03M | 80.03M |
| Repurchase of Common Stock | -446.00K | -617.00K | -627.00K | -629.00K | -409.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -5.42M | -8.13M | -5.09M | -5.09M | -5.09M |
| Cash from Financing | -5.86M | 71.25M | 74.32M | 74.32M | 74.54M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -4.61M | -22.40M | 2.57M | -5.48M | -15.31M |